Prognostic role of TEAD4 in TNBC: in-silico inhibition of the TEAD4-YAP interaction by flufenamic acid analogs.

Autor: Gupta SRR; Molecular Biology Research Laboratory, Department of Zoology, & DBC I4 Centre, Deshbandhu College, University of Delhi, New Delhi, 110019 India., Singh S; Molecular Biology Research Laboratory, Department of Zoology, & DBC I4 Centre, Deshbandhu College, University of Delhi, New Delhi, 110019 India.; Department of Biotechnology, Sharda School of Engineering and Technology, Sharda University, Greater Noida, 201310 India., Rustagi V; Molecular Biology Research Laboratory, Department of Zoology, & DBC I4 Centre, Deshbandhu College, University of Delhi, New Delhi, 110019 India., Pahuja M; Extramural Wing, Indian Council of Medical Research, New Delhi, 110029 India., Mangangcha IR; Molecular Biology Research Laboratory, Department of Zoology, & DBC I4 Centre, Deshbandhu College, University of Delhi, New Delhi, 110019 India., Rinchui M; Molecular Biology Research Laboratory, Department of Zoology, & DBC I4 Centre, Deshbandhu College, University of Delhi, New Delhi, 110019 India., Jha SK; Department of Zoology, Kalindi College, University of Delhi, New Delhi, 110008 India., Singh A; Department of Plant Molecular Biology, University of Delhi South Campus, Benito Juarez Marg, New Delhi, 110021 India., Singh IK; Molecular Biology Research Laboratory, Department of Zoology, & DBC I4 Centre, Deshbandhu College, University of Delhi, New Delhi, 110019 India.; Delhi School of Public Health, Institute of Eminence, University of Delhi, Delhi, 110007 India.
Jazyk: angličtina
Zdroj: In silico pharmacology [In Silico Pharmacol] 2024 Jul 17; Vol. 12 (2), pp. 64. Date of Electronic Publication: 2024 Jul 17 (Print Publication: 2024).
DOI: 10.1007/s40203-024-00239-8
Abstrakt: Triple-negative breast cancer (TNBC) poses a significant global health challenge due to its highly aggressive nature and invasive characteristics. Dysregulation of the Hippo pathway, a key regulator of various biological processes, is observed in TNBC, and its inhibition holds promise for impeding cancer growth. This in-silico analysis investigates the role of Transcriptional Enhanced Associate Domain 4 (TEAD4) in TNBC and its interaction with Yes Associated Protein (YAP) in cancer progression. Our results demonstrate that TEAD4 upregulation is linked to poor prognosis in TNBC, emphasizing its critical role in the disease. Moreover, we identify CID44521006, an analog of Flufenamic acid, as a potential therapeutic compound capable of disrupting the TEAD4-YAP interaction by binding to the YAP-binding domain of TEAD4. These findings underscore the significance of TEAD4 in TNBC and propose CID44521006 as a promising candidate for therapeutic intervention. The study contributes valuable insights to advance treatment options for TNBC, offering a potential avenue for the development of targeted therapies against this aggressive form of breast cancer.
Supplementary Information: The online version contains supplementary material available at 10.1007/s40203-024-00239-8.
Competing Interests: Competing interestsThe authors declare no competing interests.
(© The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature 2024. Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.)
Databáze: MEDLINE
Externí odkaz: